Management of Direct Oral Anticoagulants

General Guidelines

The American College of Cardiology recommends holding rivaroxaban for 24 hours after an accidental dose of apixaban, with resumption of regular rivaroxaban dosing the next day at the previously prescribed dose, as the half-life of apixaban is 7-8 hours and rivaroxaban is 8-9 hours in patients with normal renal function 1
No laboratory monitoring is required before resuming rivaroxaban in most cases, and no bridging anticoagulation is needed during this brief interruption, according to the French Working Group on Perioperative Hemostasis (GIHP) guidelines 2
The risk of thromboembolism is minimal with a single accidental dose, but monitoring for signs of bleeding is necessary during the transition period, with a 24-hour interruption posing minimal thromboembolic risk for most patients 3

For patients with high thromboembolic risk, such as those with mechanical heart valves, recent stroke, or recent venous thromboembolism (VTE), resuming rivaroxaban sooner (12 hours after the apixaban dose) may be considered, as recommended by the American College of Cardiology 3
In patients with significant renal impairment, the clearance of both rivaroxaban and apixaban will be prolonged, potentially requiring a longer interruption, due to their pharmacokinetic properties 1
The recommended dose of rivaroxaban is 20 mg once daily for patients with creatinine clearance (CrCl) >50 mL/min, 15 mg once daily for CrCl 30-50 mL/min, and is not recommended for CrCl <30 mL/min, with doses of 15-20 mg to be taken with food to enhance absorption 1

Routine coagulation tests (PT/INR, aPTT) are not reliable indicators of anticoagulant effect for DOACs and should not guide resumption decisions, as stated by the French Working Group on Perioperative Hemostasis (GIHP) guidelines 2
Adding heparin or low molecular weight heparin (LMWH) during this brief interruption would increase bleeding risk without clinical benefit, and is therefore not recommended by the American College of Cardiology 2
Rivaroxaban reaches therapeutic anticoagulation within 2-4 hours of administration, with a rapid onset of action 4
For low bleeding risk procedures, the American College of Cardiology recommends resuming rivaroxaban 24 hours after the procedure, and for high bleeding risk procedures, resuming 48-72 hours after the procedure, with consideration of starting with a reduced dose (10 mg once daily) for 2-3 days before increasing to the full dose 1
The American College of Cardiology suggests assessing if bleeding is controlled and source identified, and for non-major bleeding, resuming rivaroxaban once bleeding is controlled, while for major bleeding, considering delaying restart of anticoagulation until patient is stable and bleeding risk is acceptable 5